Ethyl 4-Formylpyrrole-2-Carboxylate

Process-scale preparation of bipyrrolidine NS5A replication complex inhibitors proceeds via a convergent fragment coupling where ethyl 4-formylpyrrole-2-carboxylate is converted into the electrophilic partner. The aldehyde is first protected as the 1,3-dioxolane by treatment with ethylene glycol and p-toluenesulfonic acid in refluxing toluene with azeotropic water removal. Subsequent α-bromination is executed using N‑bromosuccinimide in N,N‑dimethylformamide at −15 °C ± 2 °C, and the resulting 5‑bromo intermediate is transmetalated under Barbier-type conditions to generate the boronic ester. Material consigned to this supply chain must conform to ICH Q7 Section 12 for API starting materials; residual palladium after the coupling step is controlled to < 10 ppm per ICH Q3D Option 1, and Class 2 solvent limits (dichloromethane ≤ 600 ppm, N,N‑dimethylformamide ≤ 880 ppm) are verified by headspace GC‑FID against USP <467> Method IV. During the final convergent assembly, the protected boronate is charged at 1.05 molar equivalents relative to the halogenated pyrrole partner in a toluene/water/ethanol mixture containing potassium carbonate and tetrakis(triphenylphosphine)palladium(0) (0.02 eq); the coupled bipyrrole scaffold, after acid‑mediated acetal cleavage, typically accounts for 21–26 wt% of the free‑base API molecular mass. A critical bottleneck observed in commercial‑scale batches run in a 500 L glass‑lined reactor is the irreversible pyrrole oligomerisation triggered when residual water in tetrahydrofuran exceeds 0.05% during the subsequent low‑temperature lithiation; this necessitates on‑line Karl Fischer monitoring and nitrogen‑purged molecular‑sieve drying columns. The downstream sequence includes a Stille cross‑coupling after quenching the lithiated species with tributyltin chloride at −70 °C for 45 min and final salt formation with hydrogen chloride. The terminal dosage form is a film‑coated immediate‑release tablet containing the dihydrochloride salt of an NS5A inhibitor, indicated for chronic hepatitis C genotype 1b infection in combination with a nucleotide polymerase inhibitor.

Why Do meso-Arylporphyrin Yields Plateau Above 20 mol% Catalyst Loading in Lindsey Condensations Using Ethyl 4-Formylpyrrole-2-Carboxylate?

The aldehyde functions as the formyl‑bearing component in the statistical condensation with freshly distilled pyrrole to produce meso‑(2‑ethoxycarbonylpyrrol‑4‑yl)‑substituted porphyrinogens. Under Adler–Longo conditions (propionic acid at 140 °C, open‑air reflux) the electron‑withdrawing ester substituent suppresses pyrrole nucleophilicity, and isolated yields for the target meso‑tetraarylporphyrin remain below 10% due to dominant aldol‑type self‑condensation. The Lindsey two‑step protocol—anhydrous dichloromethane, boron trifluoride diethyl etherate (0.33 eq relative to aldehyde), ambient temperature, 1.5 h equilibration, followed by 2,3‑dichloro‑5,6‑dicyano‑1,4‑benzoquinone (DDQ, 1.2 eq)—raises the isolated yield to 14–18% after silica gel chromatography. When BF₃·OEt₂ loading exceeds 0.45 eq, acid‑catalysed ester hydrolysis generates the free carboxylic acid, which sequesters the Lewis acid and diverts the reaction toward dipyrromethane‑carbinol oligomers, thereby capping possible yield increases even with extended condensation times. Active pharmaceutical ingredients destined for photodynamic therapy are manufactured under an ISO 14644‑1 Class 8 cleanroom environment limited to 100 lux red‑filtered illumination, and the purified porphyrin must satisfy the Ph. Eur. monograph for temoporfin‑related substances (01/2023:2919) with single unspecified impurities ≤ 0.10% by HPLC at 215 nm. The custom‑synthesis charging recipe employs a pyrrole‑to‑aldehyde molar ratio of 25:1 to suppress polymeric side products; pyrrole is added in a single portion to the aldehyde‑catalyst solution under a nitrogen blanket to maintain water content below 30 ppm. After neutralisation with triethylamine, the crude reaction mixture is concentrated and purified on a silica gel column with step gradients of ethyl acetate in hexane, followed by recrystallisation from methanol/dichloromethane to achieve porphyrinic purity > 98.5%. The finished drug product is a sterile, freeze‑dried powder in amber USP Type‑I glass vials containing the meso‑substituted porphyrin hydrochloride, reconstituted prior to intravenous administration for tumour‑localising phototherapy of head and neck squamous cell carcinoma.

Spectral tuning of 4,4‑difluoro‑4‑bora‑3a,4a‑diaza‑s‑indacene (BODIPY) fluorophores for the FITC‑channel replacement window (500–530 nm emission) is routinely achieved by transforming ethyl 4‑formylpyrrole‑2‑carboxylate into a 4‑(2‑cyanovinyl) derivative that participates in the dipyrromethene forming step. In the condensation procedure, the derivative and a 3,5‑dimethylpyrrole‑2‑carboxylic acid partner are combined in refluxing 1,2‑dichloroethane containing phosphorus oxychloride (1.1 eq) under an argon sweep; the resulting crude dipyrromethene is in‑situ complexed with diisopropylethylamine and boron trifluoride etherate at 60 °C for 90 min. Bioconjugation‑grade BODIPY NHS esters supplied to in‑vitro diagnostic manufacturers must conform to ISO 13485:2016, and the fluorophore intermediate is released only after inductively coupled plasma mass spectrometry confirms lead content < 5 ppm and cadmium content < 2 ppm, because residual metals quench the singlet lifetime in cellular assays. The ethyl ester is saponified with lithium hydroxide in tetrahydrofuran/water (3:1) at 0 °C over 40 min, and the resulting acid is activated with N‑ethyl‑N′‑(3‑dimethylaminopropyl)carbodiimide hydrochloride and N‑hydroxysuccinimide in anhydrous N,N‑dimethylformamide. Conjugation to monoclonal IgG1κ antibodies is performed at an NHS‑ester‑to‑antibody molar input of 20:1 in borate‑buffered saline (pH 8.3); after Zeba spin desalting, the final fluorophore‑to‑protein ratio is spectrophotometrically measured at 504 nm (ε = 85,000 M⁻¹cm⁻¹) and the product is concentrated by tangential flow filtration across a 30 kDa polyethersulfone cartridge to a target protein concentration of 1.0 mg·mL⁻¹. Sterile filtration through a 0.22 μm membrane in a Class II biological safety cabinet precedes lyophilisation in the presence of trehalose dihydrate as a cryoprotectant. The terminal commercial product is a single‑test lyophilised cell‑staining reagent kit configured for direct immunofluorescence labelling of CD4⁺ T‑lymphocytes on Beckman Coulter CytoFLEX flow cytometers, utilising the 488 nm solid‑state laser and emission collection through a 525/40 nm band‑pass filter.

Imine-Linked Frameworks from Pyrrole Ester-Aldehyde Struts as Heterogeneous Catalysts

A two‑dimensional covalent organic framework (COF) endowed with pendant carboxylic acid sites is constructed by Schiff‑base condensation of ethyl 4‑formylpyrrole‑2‑carboxylate with 1,3,5‑tris(4‑aminophenyl)benzene. The aldehyde forms the bridging imine linkage while the ethyl ester survives the solvothermal assembly and is later hydrolysed to generate free –COOH groups that catalyse the acetalisation of benzaldehyde with ethylene glycol under continuous‑flow conditions. Feedstock qualification for reticular synthesis relies on aldehyde content determination by hydroxylamine hydrochloride titration (EP 2.4.2) with an acceptance limit ≥ 98.5%, and loss on drying at 60 °C under vacuum must be less than 0.2% to prevent off‑stoichiometric imine formation. The solvothermal reaction mixture is prepared with an aldehyde‑to‑amine functionality ratio of 1.05:1.00 in a mesitylene/1,4‑dioxane (1:4 v/v) solvent system containing aqueous acetic acid (6 M, 0.1 mL per mmol aldehyde); the slight aldehyde excess compensates for scavenging by residual water. The sealed borosilicate ampoule is subjected to three freeze‑pump‑thaw cycles before being placed in a forced‑convection oven at 120 °C for 72 hours. The resulting yellow‑orange powder is isolated by filtration and activated by Soxhlet extraction with anhydrous acetone for 24 h followed by dynamic vacuum (10⁻³ mbar) at 90 °C for 12 h. Post‑synthetic ester hydrolysis is performed with a 1 M methanolic KOH solution at 40 °C for 48 h, and the ion‑exchanged acid form is reactivated under the same thermal vacuum protocol. Batch release is governed by the Brunauer–Emmett–Teller specific surface area of N₂ adsorption at 77 K measured per ISO 9277:2010, with a lower acceptance threshold of 2,200 m²·g⁻¹. The end‑use material is supplied as a free‑flowing powder sealed under argon in valved glass bottles with a septum cap, intended for packing into fixed‑bed continuous‑flow reactors that convert benzaldehyde to benzaldehyde ethylene acetal with steady‑state conversion rates above 95% at 0.5 mL·min⁻¹ liquid hourly space velocity.

When This Pyrrole Aldehyde Constructs a Tetradentate N,O‑Ligand for Copper‑Catalysed Asymmetric Henry Additions

Condensation of ethyl 4‑formylpyrrole‑2‑carboxylate with (1R,2R)‑cyclohexane‑1,2‑diamine in refluxing anhydrous ethanol under a Dean–Stark trap furnishes the corresponding diimine, which upon further saponification with sodium hydroxide in aqueous ethanol provides a dianionic N₂O₂‑type ligand precursor. The ligand, when metallated with copper(II) acetate monohydrate, catalyses enantioselective Henry additions of nitromethane to aromatic aldehydes with enantiomeric excess reaching 89–93% (Chiralpak AD‑H column, hexane/isopropanol 90:10, 0.5 mL·min⁻¹). Supply‑chain specifications for research‑grade ligand are governed by a mutual quality agreement rather than a pharmacopoeial monograph: chiral HPLC purity must exceed 99% ee, water content by Karl Fischer titration must remain below 0.1%, and residual ethanol is controlled to < 500 ppm by static headspace GC. The catalyst stock solution is formulated by combining the ligand and Cu(OAc)₂·H₂O in a 1.00:1.05 molar ratio in methanol, stirring at ambient temperature for 90 min, evaporating the solvent, and reconstituting in dry toluene to a concentration of 0.05 mmol·mL⁻¹. In a typical batch reaction, the pre‑formed copper complex is charged at 5 mol% relative to nitromethane, and the transformation is run at −20 °C for 18 h to minimise retro‑Henry racemisation. The immediate downstream product is the enantiomerically enriched β‑nitro alcohol, which serves as a key intermediate in the manufacture of erythro‑β‑amino alcohol pharmaceuticals through Raney‑nickel hydrogenation. The commercial item is an air‑sensitive single‑use vial containing the pre‑weighed bis‑imine ligand under argon, expressly configured for kilogram‑scale asymmetric synthesis campaigns in CDMO kilo‑lab suites operating under ISO 9001:2015 management protocols.